EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Acquired Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Associated With Sertraline in Sweden—A Nationwide Population‐Based Study

Sofie Sunebo iD, Emil Nilsson iD, Martin Engvall iD, Carola Hedberg-Oldfors iD, Yan Shen iD, Inger Nennesmo, Olof Danielsson iD, Anders Oldfors iD, Hanna Appelqvist iD, Ulrika Lindgren iD

European Journal of Neurology · 2026-03 · 33 (3)

DOI: 10.1111/ene.70555 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 11.03.2026. Verfasst von Sofie Sunebo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Hauptthemen laut MEDLINE: Sertraline, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Selective Serotonin Reuptake Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Åke Wibergs Stiftelse, Neuroförbundet, Anna-Lisa och Anders Olofssons stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent studies describe an association between sertraline and acquired late‐onset multiple acyl coenzyme A dehydrogenase deficiency (MADD), a rare disorder affecting fatty acid metabolism. MADD was previously considered solely a genetic disorder caused by recessive pathogenic variants mainly in the ETFDH gene.

Methods

A nationwide population‐based registry search was conducted to identify adult patients with sertraline‐associated MADD in Sweden 2014–2024. Patients with muscle biopsy reports of lipid storage myopathy or biochemical investigations showing acylcarnitine profile suggesting MADD were included. Medical records were retrospectively reviewed.

Results

We identified 40 (30/10 female/male) patients using sertraline when diagnosed with MADD . Median age at symptom onset was 42 years and muscle weakness was the most common first symptom. All patients reported muscle symptoms during the disease course. Extra‐muscular symptoms, including sensory disturbance (29 patients) and fatigue (18 patients), were common. Most had lipid accumulation in muscle fibers, an abnormal acylcarnitine profile, a myopathic electromyography pattern, and elevated creatine kinase. Cyanocobalamin, folic acid, and proton‐pump inhibitors were the most frequent other medications at diagnosis. Five patients carried a heterozygous ETFDH variant. All patients were treated with riboflavin. Almost all (38/39) experienced clinical improvement. Acylcarnitine profile improved in all patients (31/31) with available data. The mean incidence was 1.24 patients per 100,000 adults receiving sertraline treatment per year.

Conclusions

Acquired MADD associated with sertraline is the most common type of adult‐onset MADD in Sweden. The disease is generally responsive to riboflavin treatment. Patients presenting with muscle symptoms during sertraline therapy should undergo adequate evaluation to exclude MADD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SertralineMultiple Acyl Coenzyme A Dehydrogenase DeficiencySelective Serotonin Reuptake InhibitorsHumansFemaleAdultMaleSwedenMiddle AgedOxidoreductases Acting on CH-NH Group DonorsRetrospective StudiesRegistries

Stichwörter der Autor:innen

adverse drug reactionlipid storage myopathymultiple acyl coenzyme A dehydrogenase deficiencymuscle weaknesssertraline

Substanzen

SertralineSelective Serotonin Reuptake InhibitorsOxidoreductases Acting on CH-NH Group Donors

Autor:innen und Institutionen

  • Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
  • Clinical Department of Neurology in Linköping, Region Östergötland, Linköping, Sweden.
  • Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Molecular Medicine and Surgery, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden.
  • Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg, Gothenburg, Sweden.
  • Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Region Västra Götaland, Sweden.

ORCID-Profile: Sofie Sunebo, Emil Nilsson, Martin Engvall, Carola Hedberg-Oldfors, Yan Shen, Olof Danielsson, Anders Oldfors, Hanna Appelqvist, Ulrika Lindgren

Förderung

  • Åke Wibergs Stiftelse
  • Neuroförbundet
  • Anna-Lisa och Anders Olofssons stiftelse
  • Region Östergötland
  • Swedish governmental funding of clinical research (ALF)
  • The Research Fund for Neuromuscular Disorders in West Sweden
  • Vetenskapsrådet
  • Göteborgs Läkaresällskap

Zitieren

APA

Sunebo, S., Nilsson, E., Engvall, M., Hedberg-Oldfors, C., Shen, Y., Nennesmo, I., Danielsson, O., Oldfors, A., Appelqvist, H., & Lindgren, U. (2026). Acquired Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Associated With Sertraline in Sweden—A Nationwide Population‐Based Study. European Journal of Neurology, 33(3). https://doi.org/10.1111/ene.70555

Vancouver

Sunebo S, Nilsson E, Engvall M, Hedberg-Oldfors C, Shen Y, Nennesmo I, et al. Acquired Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Associated With Sertraline in Sweden—A Nationwide Population‐Based Study. European Journal of Neurology. 2026;33(3). doi:10.1111/ene.70555

BibTeX
@article{Sunebo2026,
  author = {Sunebo, Sofie and Nilsson, Emil and Engvall, Martin and Hedberg-Oldfors, Carola and Shen, Yan and Nennesmo, Inger and Danielsson, Olof and Oldfors, Anders and Appelqvist, Hanna and Lindgren, Ulrika},
  title = {Acquired Multiple Acyl‐Coenzyme A Dehydrogenase Deficiency Associated With Sertraline in Sweden—A Nationwide Population‐Based Study},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/ene.70555}
}
Kostenlos starten →